MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2710-2716

  Ryan, Bríd M ^a   Calhoun, Kara M ^a   Pine, Sharon R ^b   Bowman, Elise D ^a   Robles, Ana I ^a   Ambs, Stefan ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

lung cancer; SNP285; SNP309

Indexed keywords

PROTEIN MDM2;

AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ENDOMETRIUM CANCER; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 84867076867     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27573     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Underwood JM, Townsend JS, Tai E, et al. Racial and regional disparities in lung cancer incidence. Cancer 2012; 118: 1910-18.
3. Wade M, Wang YV, Wahl GM,. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20: 299-309.
4. Jones SN, Roe AE, Donehower LA, et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-8.
5. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
6. Wilkening S, Bermejo JL, Hemminki K,. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007; 28: 2262-7.
7. Wasielewski M, Nagel JH, Brekelmans C, et al. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 2007; 104: 153-7.
8. Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006; 98: 911-19.
9. Lind H, Zienolddiny S, Ekstrom PO, et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006; 119: 718-21.
10. Jun HJ, Park SH, Lee WK, et al. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog 2007; 46: 100-5.
11. Park SH, Choi JE, Kim EJ, et al. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 2006; 54: 19-24.
12. Chua HW, Ng D, Choo S, et al. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 2010; 10: 88.
13. Pine SR, Mechanic LE, Bowman ED, et al. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 1559-61.
14. Hu Z, Ma H, Lu D, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 2006; 118: 1275-8.
15. Dong J, Ren B, Hu Z, et al. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinog 2011; 50: 433-8.
16. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol 2007; 25: 2243-7.
17. Paulin FE, O'Neill M, McGregor G, et al. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 2008; 8: 281.
18. Knappskog S, Bjornslett M, Myklebust LM, et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell 2011; 19: 273-82.
19. Knappskog S, Lonning PE,. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget 2011; 2: 251-8.
20. Knappskog S, Trovik J, Marcickiewicz J, et al. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer, 2011 Nov 24. [Epub ahead of print].
21. Goodman JE, Mechanic LE, Luke BT, et al. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 2006; 118: 1790-7.
22. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 1997; 75: 1302-8.
23. Bond GL, Menin C, Bertorelle R, et al. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 2006; 43: 950-2.
24. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66: 5104-10.
25. Saville B, Wormke M, Wang F, et al. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000; 275: 5379-87.